Skip to content

Prospective, randomized, open-label clinical study of whether preserving vagus nerve branches during single-aperture thoracoscopic lung cancer surgery promotes rapid recovery in patients

Prospective, randomized, open-label clinical study of whether preserving vagus nerve branches during single-aperture thoracoscopic lung cancer surgery promotes rapid recovery in patients

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400090347
Enrollment
Unknown
Registered
2024-09-27
Start date
2024-10-01
Completion date
Unknown
Last updated
2024-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Experimental group:Keep the vagus nerve branches
control group:The traditional operation method, does not retain the vagus nerve branches

Sponsors

Liaoning Cancer Hospital &Insitute
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients with stage IA-IB non-small-cell peripheral lung cancer 2. No preoperative surgery taboo 3. The probability of mediastinal lymph node metastasis assessed by preoperative imaging or PET-CT is low 4. The pathology of infiltrating adenocarcinoma or simultaneous multiple primary lung cancer in the same lobe; 5. Aged between 18-75 years; 6: The surgical method can only be lobectomy 7. Patients with ASA I - III level 8 patients without emergency surgery

Exclusion criteria

Exclusion criteria: (1) patients with previous radiotherapy and chemotherapy; (2) incomplete data; (3) After enrollment, the patient's condition changed and emergency surgery was confirmed by the doctor in charge; (4) preoperative cough, cough level greater than or equal to 3 points; (5) patients with preoperative arrhythmia; (6) patients with preoperative constipation and diarrhea; (7) preoperative heart disease, such as severe heart failure; (8) pregnant or lactating women; (9) with severe mental illness; (10) history of other malignant diseases within 5 years; (11) history of unstable angina or myocardial infarction within 6 months; (12) history of cerebral infarction or cerebral hemorrhage within 6 months; (13) Simultaneous surgical treatment of other diseases; (14) because of psychological, family or social reason to cooperate with this study, refused to sign the informed consent of patients;

Design outcomes

Primary

MeasureTime frame
Whether there was conversion to thoracotomy and the reasons for conversion;Intraoperative blood loss;blood transfusion volume;Location of the tumor;Operation cure degree (R0 / R1 / R2);pain score;extubation time;drainagevolume (Average drainage volume, drainage volume in the first three days);hospital stays;histological type;histological grade;Vascular invasion;Nerve invasion;The lungs spread;Number and the total number of lymph node groups;TNM staging;Incision complications (infection, effusion, dehiscence, poor healing, etc.);The activity of the chest cavity is bleeding;hoarseness;chylothorax;pneumonia;Cardiovascular and cerebrovascular events (including thrombosis, embolism, etc.);CRP;For the first time away from the bed activity time;For the first time the anus exhaust/bowel bowel sounds/time;After surgery to discharge the daily highest temperature (?);The number of sputum suction postoperative bronchoscopy;Postoperative hospital stay (d);CAP;chronic pain;constipation;cough;

Secondary

MeasureTime frame
time of operation;modus operandi;The number of lymph nodes dissected;length of incision;Surgery related complications: intraoperative bleeding and damage (vital organs and structures, including blood vessel damage to extra blood loss);anesthesia related complication;

Countries

China

Contacts

Public ContactLiang Zhang

Liaoning Cancer Hospital &Insitute

13998288410@163.com+86 189 0091 8167

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026